Relating To Mental Health.
SB1042 establishes a two-year Mental Health Emerging Therapies Pilot Program within the Hawaii Office of Wellness and Resilience. The program is intended to support clinical research and development of emerging mental health and behavioral health treatments, especially psychedelic and entactogenic therapies such as MDMA- and psilocybin-related treatments that have received or may receive FDA breakthrough-therapy designation. The bill frames the program as a response to Hawaii’s mental health crisis and the elevated rates of suicide and PTSD among veterans.
Under the bill, the office may partner with public and private entities, fund phase three clinical trials and related implementation studies, support education and training for mental health professionals, promote public education and harm reduction, and make recommendations to expand patient access and support services. The office may also contract with a third party to administer funds and may adopt rules without following chapter 91, Hawaii Revised Statutes, to run the pilot. The program would report to the Legislature in 2026 and 2027 and would sunset on June 30, 2027. The bill also appropriates general funds for fiscal years 2025-2026 and 2026-2027, though the dollar amount is left blank in the text provided.
The bill would create a new, temporary state pilot program and direct state money toward research, training, and implementation planning for emerging therapies. It does not itself legalize psychedelic treatment broadly, but it defines “emerging therapies” to include psychedelic or entactogenic compounds that are in FDA-regulated trials, approved for interstate commerce, or approved for medical use under state law. In practical terms, it would expand the role of the Office of Wellness and Resilience and could influence future policy by generating findings, recommendations, and proposed legislation.
The general sentiment reflected in the available voting history is strongly supportive. The bill passed the Senate Health and Human Services Committee 5-0 with amendments and later passed the Senate Ways and Means Committee 13-0 unamended, suggesting broad bipartisan or at least unanimous committee approval. The bill’s findings emphasize urgent need, veteran suicide prevention, and evidence-based innovation, which likely contributed to favorable consideration.
The main points of contention are implicit rather than explicit in the record provided. The bill’s focus on psychedelic and entactogenic therapies, the use of state funds for clinical research, and the authority to adopt rules without chapter 91 procedures could raise concerns about safety, regulatory oversight, and the appropriateness of public funding for emerging treatments. Supporters appear to view these therapies as promising, especially for treatment-resistant PTSD and depression, while any opposition would likely center on scientific uncertainty, implementation safeguards, and the use of taxpayer dollars.
SB1042 would add a temporary pilot program to Hawaii law through the Office of Wellness and Resilience, authorizing the office to fund and coordinate research, training, education, harm reduction, and access planning for emerging mental health therapies. It would appropriate state general funds for two fiscal years, allow the office to contract with a third-party administrator, and permit rulemaking outside chapter 91, HRS, for program administration. The bill would not permanently amend existing mental health treatment statutes, but it would create a new state-funded structure that could inform future legislation and policy on psychedelic-assisted therapy and related behavioral health interventions.
The available legislative history shows strong support for the measure. It passed the Senate Health and Human Services Committee 5-0 with amendments and the Senate Ways and Means Committee 13-0 unamended, indicating broad agreement on the bill’s goals. The bill’s findings and structure suggest a generally favorable view of emerging therapies as a potential tool for addressing PTSD, depression, and veteran suicide, with the Legislature positioning the pilot as an evidence-gathering and access-expansion effort rather than a full-scale treatment mandate.
No formal opposition is reflected in the provided transcripts or vote totals, but the bill’s likely areas of debate are clear from its design. Potential concerns include the use of public funds for psychedelic-related research, the scientific and regulatory uncertainty surrounding emerging therapies, and the bill’s authorization for the Office of Wellness and Resilience to adopt rules without chapter 91 procedures. Supporters appear focused on innovation, veteran mental health, and access to promising treatments, while skeptics would likely question safety, oversight, and whether the state should fund therapies still under clinical development.